Clinical trials: Patients Receiving Induction/Consolidation Chemotherapy
Patients With Acute Myeloid Leukemia, Patients Receiving Induction/Consolidation Chemotherapy
Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia
The main component in the treatment of acute myeloid leukemia (AML) is consist of anthracycline (such as daunorubicin or idarubicin) and cytarabine.
- Trial name
- NCT01106144
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center